Abstract
Acyclovir (ACV) therapy, topical or systemic, showed a significantly high therapeutic efficacy for facial Herpes Simplex Virus (HSV) infection in hairless mice. When topical ACV treatment was initiated very early, i.e., three h post-inoculation, the number of mice with latent HSV infection in their trigeminal ganglia was significantly reduced. These results indicate that ACV clearly merits further investigation as an antiviral agent for therapy of orofacial HSV infections.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
